ALLK

As recently shown, investing in Allakos (NASDAQ:ALLK) proves the inherent danger within the biopharmaceutical sector. After reaching a 52-week high of more than $157, ALLK… Read More »Allakos Is A Cautionary Tale Of Biopharmaceutical Investing